RenovoRx, Inc. (NASDAQ:RNXT) Insider Ramtin Agah Purchases 15,000 Shares

RenovoRx, Inc. (NASDAQ:RNXT) insider Ramtin Agah purchased 15,000 shares of the stock in a transaction that occurred on Tuesday, April 15th. The stock was bought at an average cost of $0.90 per share, with a total value of $13,500.00. Following the acquisition, the insider now owns 1,113,460 shares of the company’s stock, valued at $1,002,114. This represents a 1.37 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Ramtin Agah also recently made the following trade(s):

• On Friday, April 11th, Ramtin Agah acquired 20,000 shares of RenovoRx stock. The stock was purchased at an average price of $0.80 per share, for a total transaction of $16,000.00.
• On Tuesday, April 8th, Ramtin Agah purchased 26,000 shares of RenovoRx stock. The shares were purchased at an average cost of $0.84 per share, for a total transaction of $21,840.00.

RenovoRx Stock Performance

Shares of RenovoRx stock opened at $1.02 on Friday. The firm has a fifty day moving average of $0.97 and a two-hundred day moving average of $1.13. The stock has a market capitalization of $37.28 million, a price-to-earnings ratio of -1.79 and a beta of 1.12. RenovoRx, Inc. has a 52 week low of $0.75 and a 52 week high of $1.69.

RenovoRx (NASDAQ:RNXT) last released its earnings results on Monday, March 31st. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.17 million. As a group, research analysts forecast that RenovoRx, Inc. will post -0.4 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Citadel Advisors LLC bought a new position in shares of RenovoRx during the fourth quarter worth $49,000. Renaissance Technologies LLC acquired a new stake in RenovoRx during the 4th quarter worth $84,000. Finally, Geode Capital Management LLC lifted its holdings in RenovoRx by 61.9% during the third quarter. Geode Capital Management LLC now owns 232,937 shares of the company’s stock worth $247,000 after acquiring an additional 89,018 shares in the last quarter. Institutional investors and hedge funds own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of RenovoRx in a report on Friday, April 4th.

RenovoRx Company Profile

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.